Childhood Kidney Diseases

  • 제26권1호
  • /
  • Pages.31-39
  • /
  • 2022
  • /
  • 2384-0242(pISSN)
  • /
  • 2384-0250(eISSN)
대한소아신장학회 (Korean Society of Pediatric Nephrology)
권호 표지
DOI QR코드

DOI QR Code

Alport syndrome: new advances in the last decade

  • Kim, Ji Hyun (Department of Pediatrics, Seoul National University Bundang Hospital)
  • 투고 : 2022.03.16
  • 심사 : 2022.05.04
  • 발행 : 2022.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Alport syndrome (AS) is a progressive hereditary nephritis that is often accompanied by sensorineural hearing loss and ocular abnormalities. It is inherited in three modes of X-linked AS (XLAS), autosomal recessive AS (ARAS), and autosomal dominant AS (ADAS). XLAS is caused by pathogenic variants in COL4A5, while ARAS and ADAS are caused by those in COL4A3 or COL4A4. There is currently no curative treatment for AS; however, angiotensin-converting enzyme inhibitors (ACEi) can improve the outcome of AS. In the past decade, multiple studies have shown that early intervention with ACEi upon isolated microscopic hematuria or microalbuminuria could delay disease progression, and early diagnosis is crucial for early treatment. Therefore, a new classification of AS based on molecular diagnoses has been proposed, including the paradigm shift of re-classifying female "carriers" to "patients" and "thin basement membrane nephropathy" to "ADAS." In addition, with the detection of COL4A mutations in some patients with biopsy-confirmed IgA nephropathy, focal segmental glomerulosclerosis, and chronic kidney disease of unknown origin, it is suggested that the phenotype of AS should be expanded. In this review, we highlight the landmark studies and guidelines published over the past decade and introduce strategies for early diagnosis and treatment to improve the outcomes of AS.

키워드

참고문헌

  1. Nozu K, Takaoka Y, Kai H, Takasato M, Yabuuchi K, Yamamura T, et al. Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome. Kidney Res Clin Pract 2020;39:402-13. https://doi.org/10.23876/j.krcp.20.111
  2. Kashtan CE, Gross O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol 2021;36:711-9. https://doi.org/10.1007/s00467-020-04819-6
  3. Savige J, Ariani F, Mari F, Bruttini M, Renieri A, Gross O, et al. Expert consensus guidelines for the genetic diagnosis of Alport syndrome. Pediatr Nephrol 2019;34:1175-89. https://doi.org/10.1007/s00467-018-3985-4
  4. Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Kidney Int 2020;97:1117-29. https://doi.org/10.1016/j.kint.2020.02.010
  5. Nozu K, Nakanishi K, Abe Y, Udagawa T, Okada S, Okamoto T, et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol 2019;23:158-68. https://doi.org/10.1007/s10157-018-1629-4
  6. Boutaud A, Borza DB, Bondar O, Gunwar S, Netzer KO, Singh N, et al. Type IV collagen of the glomerular basement membrane: evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J Biol Chem 2000;275:30716-24. https://doi.org/10.1074/jbc.M004569200
  7. Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 2010;21:876-83. https://doi.org/10.1681/ASN.2009070784
  8. Jais JP, Knebelmann B, Giatras I, Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 2000;11:649-57. https://doi.org/10.1681/ASN.V114649
  9. Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant 2002;17:1218-27. https://doi.org/10.1093/ndt/17.7.1218
  10. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol 2003;14:2603-10. https://doi.org/10.1097/01.ASN.0000090034.71205.74
  11. Yamamura T, Nozu K, Fu XJ, Nozu Y, Ye MJ, Shono A, et al. Natural history and genotype-phenotype correlation in female X-linked Alport syndrome. Kidney Int Rep 2017;2:850-5. https://doi.org/10.1016/j.ekir.2017.04.011
  12. Lee JM, Nozu K, Choi DE, Kang HG, Ha IS, Cheong HI. Features of autosomal recessive Alport syndrome: a systematic review. J Clin Med 2019;8:178. https://doi.org/10.3390/jcm8020178
  13. Oka M, Nozu K, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, et al. Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol 2014;29:1535-44. https://doi.org/10.1007/s00467-014-2797-4
  14. Kamiyoshi N, Nozu K, Fu XJ, Morisada N, Nozu Y, Ye MJ, et al. Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome. Clin J Am Soc Nephrol 2016;11:1441-9. https://doi.org/10.2215/CJN.01000116
  15. Kashtan CE. Alport syndrome: an inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore) 1999;78:338-60. https://doi.org/10.1097/00005792-199909000-00005
  16. Sessa A, Meroni M. Alport's syndrome: Orphanet encyclopedia [Internet]. Paris: Orphanet; 2001 [cited 2022 Mar 2]. Available from: https://www.orpha.net.
  17. Savige J, Sheth S, Leys A, Nicholson A, Mack HG, Colville D. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol 2015;10:703-9. https://doi.org/10.2215/CJN.10581014
  18. Adam J, Connor TM, Wood K, Lewis D, Naik R, Gale DP, et al. Genetic testing can resolve diagnostic confusion in Alport syndrome. Clin Kidney J 2014;7:197-200. https://doi.org/10.1093/ckj/sft144
  19. Yao XD, Chen X, Huang GY, Yu YT, Xu ST, Hu YL, et al. Challenge in pathologic diagnosis of Alport syndrome: evidence from correction of previous misdiagnosis. Orphanet J Rare Dis 2012;7:100. https://doi.org/10.1186/1750-1172-7-100
  20. Warady BA, Agarwal R, Bangalore S, Chapman A, Levin A, Stenvinkel P, et al. Alport syndrome classification and management. Kidney Med 2020;2:639-49. https://doi.org/10.1016/j.xkme.2020.05.014
  21. Heidet L, Gubler MC. The renal lesions of Alport syndrome. J Am Soc Nephrol 2009;20:1210-5. https://doi.org/10.1681/ASN.2008090984
  22. Hashimura Y, Nozu K, Kaito H, Nakanishi K, Fu XJ, Ohtsubo H, et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain. Kidney Int 2014;85:1208-13. https://doi.org/10.1038/ki.2013.479
  23. Nakanishi K, Yoshikawa N, Iijima K, Kitagawa K, Nakamura H, Ito H, et al. Immunohistochemical study of alpha 1-5 chains of type IV collagen in hereditary nephritis. Kidney Int 1994;46:1413-21. https://doi.org/10.1038/ki.1994.413
  24. IgA nephropathy combined with thin basement membrane nephropathy in children. Kidney Res Clin Pract 2013;32:194-5. https://doi.org/10.1016/j.krcp.2013.10.004
  25. Lennon R, Fornoni A. Could this be Alport syndrome? Clin J Am Soc Nephrol 2021;16:1743-5. https://doi.org/10.2215/CJN.00120121
  26. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, et al. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet 2021;29:1186-97. https://doi.org/10.1038/s41431-021-00858-1
  27. Yamamura T, Horinouchi T, Nagano C, Omori T, Sakakibara N, Aoto Y, et al. Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int 2020;98:1605-14. https://doi.org/10.1016/j.kint.2020.06.038
  28. Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003;63:438-46. https://doi.org/10.1046/j.1523-1755.2003.00779.x
  29. Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012;81:494-501. https://doi.org/10.1038/ki.2011.407
  30. Gross O, Tonshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome. Kidney Int 2020;97:1275-86. https://doi.org/10.1016/j.kint.2019.12.015
  31. Groopman EE, Marasa M, Cameron-Christie S, Petrovski S, Aggarwal VS, Milo-Rasouly H, et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med 2019;380:142-51. https://doi.org/10.1056/NEJMoa1806891
  32. Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N, et al. Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 2016;31:961-70. https://doi.org/10.1093/ndt/gfv325
  33. Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV α345. A position paper of the Alport Syndrome Classification Working Group. Kidney Int 2018;93:1045-51. https://doi.org/10.1016/j.kint.2017.12.018
  34. Grunfeld JP, Noel LH, Hafez S, Droz D. Renal prognosis in women with hereditary nephritis. Clin Nephrol 1985;23:267-71.
  35. Rana K, Wang YY, Powell H, Jones C, McCredie D, Buzza M, et al. Persistent familial hematuria in children and the locus for thin basement membrane nephropathy. Pediatr Nephrol 2005;20:1729-37. https://doi.org/10.1007/s00467-005-2034-2
  36. Imafuku A, Nozu K, Sawa N, Nakanishi K, Ubara Y. How to resolve confusion in the clinical setting for the diagnosis of heterozygous COL4A3 or COL4A4 gene variants? Discussion and suggestions from nephrologists. Clin Exp Nephrol 2020;24:651-6. https://doi.org/10.1007/s10157-020-01880-1
  37. Yamamura T, Nozu K, Minamikawa S, Horinouchi T, Sakakibara N, Nagano C, et al. Comparison between conventional and comprehensive sequencing approaches for genetic diagnosis of Alport syndrome. Mol Genet Genomic Med2019;7:e883.
  38. Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 2013;28:5-11. https://doi.org/10.1007/s00467-012-2138-4
  39. ESCAPE Trial Group, Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009;361:1639-50. https://doi.org/10.1056/NEJMoa0902066
  40. Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, et al. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol 2009;24:845-9. https://doi.org/10.1007/s00467-008-1006-8
  41. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011;80:868-78. https://doi.org/10.1038/ki.2011.195
  42. Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, et al. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 2004;19:1716-23. https://doi.org/10.1093/ndt/gfh219
  43. Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, et al. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome. Pediatr Nephrol 2013;28:737-43. https://doi.org/10.1007/s00467-012-2372-9
  44. van den Belt SM, Heerspink HJL, Gracchi V, de Zeeuw D, Wuhl E, Schaefer F, et al. Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD. J Am Soc Nephrol 2018;29:2225-33. https://doi.org/10.1681/ASN.2018010036
  45. Kaito H, Nozu K, Iijima K, Nakanishi K, Yoshiya K, Kanda K, et al. The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol 2006;21:1824-9. https://doi.org/10.1007/s00467-006-0270-8
  46. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-8. https://doi.org/10.1038/nm.1857
  47. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481-508. https://doi.org/10.2215/CJN.04800908
  48. Callis L, Vila A, Carrera M, Nieto J. Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int 1999;55:1051-6. https://doi.org/10.1046/j.1523-1755.1999.0550031051.x
  49. Callis L, Vila A, Nieto J, Fortuny G. Effect of cyclosporin A on proteinuria in patients with Alport's syndrome. Pediatr Nephrol 1992;6:140-4. https://doi.org/10.1007/BF00866293
  50. Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Grunfeld JP, Niaudet P. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol 2007;22:57-63. https://doi.org/10.1007/s00467-006-0227-y
  51. Massella L, Muda AO, Legato A, Di Zazzo G, Giannakakis K, Emma F. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol 2010;25:1269-75. https://doi.org/10.1007/s00467-010-1484-3
  52. Kim JH, Lee DH, Lee B, Lim SH, Ahn YH, Kang HG, et al. Renal syndromic hearing loss is common in childhood-onset chronic kidney disease. J Korean Med Sci 2020;35:e364. https://doi.org/10.3346/jkms.2020.35.e364
  53. Alves FR, de A Quintanilha Ribeiro F. Revision about hearing loss in the Alport's syndrome, analyzing the clinical, genetic and bio-molecular aspects. Braz J Otorhinolaryngol 2005;71:813-9. https://doi.org/10.1016/S1808-8694(15)31253-2
  54. Zhang X, Zhang Y, Zhang Y, Gu H, Chen Z, Ren L, et al. X-linked Alport syndrome: pathogenic variant features and further auditory genotype-phenotype correlations in males. Orphanet J Rare Dis 2018;13:229. https://doi.org/10.1186/s13023-018-0974-4
  55. Reata Pharmaceuticals. Reata announces positive results from year 2 of the pivotal phase 3 CARDINAL study of bardoxolone methyl in patients with Alport syndrome [Internet]. Reata Plano: Pharmaceuticals; 2020 [cited 2022 Mar 5]. Available from: https://www.reatapharma.com/investors/news/news-details/2020/Reata-Announces-Positive-Results-From-Year-2-of-the-Pivotal-Phase-3-CARDINAL-Study-of-Bardoxolone-Methyl-in-Patients-with-Alport-Syndrome/default.aspx.
  56. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013;369:2492-503. https://doi.org/10.1056/NEJMoa1306033
  57. Gomez IG, MacKenna DA, Johnson BG, Kaimal V, Roach AM, Ren S, et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 2015;125:141-56. https://doi.org/10.1172/JCI75852